Create issue ticket

479 Possible Causes for 1, Kinase, MEK

Show results in: Română

  • Sunburn

    Matsui M 1 , Tanaka K 1 , Higashiguchi N 1 , Okawa H 1 , Yamada Y 2 , Tanaka K 3 , Taira S 1 , Aoyama T 1 , Takanishi M 1 , Natsume C 1 , Takakura Y 1 , Fujita N 4 , Hashimoto[ncbi.nlm.nih.gov] […] ascorbic acid or its esters. 7 , 19 There is also substantial evidence that antioxidants act as anti-inflammatory agents on a cellular level by inhibiting activation of kinases[doi.org] Inhibition of the Ras/Raf/MEK/ERK and RET Kinase Pathways with the Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Medullary[web.archive.org]

  • Digestive System Melanoma

    The most frequently reported site is in the esophagus and anorectum. [1] Symptoms of a digestive system melanoma may be nonspecific, including blood in the stool , stomach[rarediseases.info.nih.gov] They affect the MAP kinase pathway, which is involved in the regulation of cell growth, differentiation, and apoptosis.[symptoma.com] (Updated 2011 May 1). Cystic fibrosis. MedlinePlus Medical Encyclopedia [On-line information]. Available online at . Accessed July 2011. Delgado, J. and Grenache, D.[labtestsonline.it]

  • Chronic Myeloid Leukemia

    Sorrenti V 1 , Pittalà V 2 , Romeo G 1 , Amata E 1 , Dichiara M 1 , Marrazzo A 1 , Turnaturi R 1 , Prezzavento O 1 , Barbagallo I 1 , Vanella L 1 , Rescifina A 1 , Floresta[ncbi.nlm.nih.gov] […] the Abl kinase domain, are currently competing.[doi.org] , ERK, C-RAF, P-AKT, P-MEK and P-ERK).[ncbi.nlm.nih.gov]

  • Ataxia Telangiectasia

    In the current study, we found that phospho-p21-activated kinase-1 (Pak1) and Pak1 expression was high in clinical samples of sunlight-induced premalignant skin lesions assessed[ncbi.nlm.nih.gov] Mechanistically, ATM mediates crosstalk between the prosurvival MEK/ERK and AKT/mTOR pathways.[ncbi.nlm.nih.gov] Compound 27g was also significantly more selective against other kinases than 4.[ncbi.nlm.nih.gov]

  • T-cell Acute Lymphoblastic Leukemia

    Seki M 1 , Kimura S 1, 2 , Isobe T 1 , Yoshida K 3 , Ueno H 3 , Nakajima-Takagi Y 4 , Wang C 4 , Lin L 5 , Kon A 3 , Suzuki H 3 , Shiozawa Y 1 , Kataoka K 3 , Fujii Y 3 ,[ncbi.nlm.nih.gov] KEYWORDS: ETP-ALL; PIM kinase; T-ALL; ponatinib; tyrosine kinase inhibitor[ncbi.nlm.nih.gov] Here, we show that inhibiting both the MEK and PI3K-AKT pathways synergistically prevents the proliferation of BaF3 cells expressing mutant IL7Ra, JAK and RAS.[ncbi.nlm.nih.gov]

  • Philadelphia Chromosome Positive Chronic Myeloid Leukemia

    This phase 1/2 study evaluated the safety and pharmacokinetics (part 1) and efficacy and safety (part 2) of bosutinib in Japanese Philadelphia chromosome-positive (Ph ) chronic-phase[ncbi.nlm.nih.gov] The Src-family kinases (SFKs) are one such pathway and have been implicated in imatinib resistance.[ncbi.nlm.nih.gov] "JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis". Leukemia. 18 (2): 189–218. doi : 10.1038/sj.leu.2403241. PMID 14737178.[en.wikipedia.org]

  • Chronic Phase of Chronic Myeloid Leukemia

    […] year after onset, with t(9;22)(q34;q11.2), 8, 14, 21, and der(1)(p36).[ncbi.nlm.nih.gov] Abstract OBJECTIVE: This multicenter cooperative study aimed to analyze the adverse events (AEs) associated with tyrosine kinase inhibitors (TKIs) used as initial treatment[ncbi.nlm.nih.gov] Several signaling cascades are modulated accordingly: Increased proliferation results from disturbance of the Ras/Raf/MEK/ERK pathway, interaction with members of the JAK[symptoma.com]

  • Gastrointestinal Stromal Tumor

    (NF-1).[ncbi.nlm.nih.gov] With the introduction of imatinib (Gleevec), an oral tyrosine kinase inhibitor (TKI) that selectively targets KIT, ABL, BCR-ABL, and PDGFR, up to 80% of patients experience[onclive.com] The addition of the MEK inhibitor PD-325901 or binimetinib further decreased downstream KIT signaling.[ncbi.nlm.nih.gov]

  • Myeloproliferative Disease

    (PT-1) cohort.[doi.org] We investigated the role of the cytoplasmic tyrosine kinase JAK2 in patients with a myeloproliferative disorder.[ncbi.nlm.nih.gov] Our data demonstrate that deregulated Raf/MEK/ERK signaling is integral to the growth of Kras-mediated myeloproliferative neoplasms and further suggest that MEK inhibition[ncbi.nlm.nih.gov]

  • Neurofibroma

    Molecular genetics of neurofibromatosis type 1 (NF1).[doi.org] Extracellular signal-regulated kinase-dependent proliferation is mediated through the protein kinase A/B-Raf pathway in human uveal melanoma cells.[mct.aacrjournals.org] About selumetinib Selumetinib (AZD6244 or ARRY-142886) is an oral, highly selective MEK 1/2 inhibitor.[raredr.com]